Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income

Dividend stocks are the best option for investors looking for consistent passive income. These are companies with stable cash flows, healthy balance sheets, and a long history of rewarding shareholders with steady dividends. Here are two solid dividend stocks that stand out for providing consistent income and long-term stability, even in volatile markets.

Johnson & Johnson (JNJ) is a global healthcare company that makes prescription drugs that treat serious and chronic diseases and also makes medical devices and technologies used in hospitals. JNJ’s diversified business generates stable, resilient revenue and strong cash flow, allowing it to pay recurring dividends. JNJ...

Fundamentals

See More
  • Market Capitalization, $K 526,551,392
  • Shares Outstanding, K 2,409,295
  • Annual Sales, $ 88,821 M
  • Annual Income, $ 14,066 M
  • EBIT $ 29,302 M
  • EBITDA $ 36,641 M
  • 60-Month Beta 0.34
  • Price/Sales 5.78
  • Price/Cash Flow 16.28
  • Price/Book 6.49

Options Overview Details

View History
  • Implied Volatility 22.13% (-0.92%)
  • Historical Volatility 19.69%
  • IV Percentile 93%
  • IV Rank 42.70%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 7) 6.76 (3.08%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 31,308
  • Volume Avg (30-Day) 22,655
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 452,162
  • Open Int (30-Day) 414,583
  • Expected Range 212.81 to 226.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.50
  • Number of Estimates 8
  • High Estimate 2.56
  • Low Estimate 2.41
  • Prior Year 2.04
  • Growth Rate Est. (year over year) +22.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
200.91 +9.29%
on 01/05/26
219.75 -0.08%
on 01/15/26
+5.40 (+2.52%)
since 12/15/25
3-Month
184.66 +18.91%
on 10/29/25
219.75 -0.08%
on 01/15/26
+28.40 (+14.86%)
since 10/15/25
52-Week
141.50 +55.17%
on 04/09/25
219.75 -0.08%
on 01/15/26
+74.60 (+51.46%)
since 01/15/25

Most Recent Stories

More News
2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income

These two income stocks can weather every cycle.

JNJ : 219.57 (+0.47%)
PG : 144.63 (-1.18%)
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

TECVAYLI ® alone reduced risk of disease progression or death by 71% in a high unmet need population MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI ® ...

JNJ : 219.57 (+0.47%)
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

New CAPLYTA ® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented

JNJ : 219.57 (+0.47%)
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 81.36 (+2.56%)
VHT : 291.96 (-0.53%)
NVO : 57.12 (-3.04%)
JNJ : 219.57 (+0.47%)
MRK : 110.97 (-0.04%)
HCA : 483.80 (+1.04%)
ABBV : 216.75 (-2.32%)
UNH : 338.96 (+1.19%)
ELV : 381.93 (+2.44%)
PFE : 25.89 (+1.21%)
TSLA : 438.57 (-0.14%)
LLY : 1,032.97 (-3.76%)
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months

JNJ : 219.57 (+0.47%)
Earnings Preview: What to Expect From Kenvue’s Report

Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.

KMB : 100.41 (+1.27%)
$SPX : 6,944.47 (+0.26%)
JNJ : 219.57 (+0.47%)
KVUE : 17.26 (+0.82%)
XLP : 82.37 (+0.17%)
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates Agreement provides Johnson & Johnson pharmaceutical products...

JNJ : 219.57 (+0.47%)
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

- Number of Lawsuits Increases Fivefold to Over 2,100 Since May - FDA Approves Brain Tumour Warning Global pharmaceutical company...

RKT.LN : 6,146.000 (-0.61%)
JNJ : 219.57 (+0.47%)
PFE : 25.89 (+1.21%)
Should You Chase the Rally in Alumis Stock Today?

Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

JNJ : 219.57 (+0.47%)
ALMS : 24.17 (-0.70%)
BMY : 56.62 (-0.70%)
Johnson & Johnson Submits OTTAVAâ„¢ Robotic Surgical System to the U.S. Food and Drug Administration

Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures used to support application for De Novo classification Second IDE approved...

JNJ : 219.57 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 224.75
2nd Resistance Point 222.25
1st Resistance Point 220.91
Last Price 219.57
1st Support Level 217.07
2nd Support Level 214.57
3rd Support Level 213.23

See More

52-Week High 219.75
Last Price 219.57
Fibonacci 61.8% 189.86
Fibonacci 50% 180.63
Fibonacci 38.2% 171.39
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar